×

Biotech stocks too risky?

1:57 PM ET Fri, 5 Feb 2016

RBC Capital Markets BioTech Analyst Michael Yee and CastleArk Management President & CIO Jerry Castellini discuss the bull and bear cases for biotech stocks.